{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:54:59Z","timestamp":1783004099065,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"German Federal Institute for Drugs and Medical Devices"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.reprotox.2017.04.007","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T18:47:55Z","timestamp":1493837275000},"page":"101-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Leflunomide \u2013 A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database"],"prefix":"10.1016","volume":"71","author":[{"given":"Corinna","family":"Weber-Schoendorfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Tissen-Diabat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reprotox.2017.04.007_bib0005","unstructured":"J.S. Smolen, R. Landew\u00e9. Eular Recommendations for the Management of Rheumatoid Arthritis \u2013 2016 Update. http:\/\/www.eular.org\/myUploadData\/files\/EULAR RA Management recommendations 2016 update June 2016-c_2.pdfAvailable from: http:\/\/www.eular.org\/myUploadData\/files\/EULAR%20RA%20Management%20recommendations%202016%20update%20June%202016-c_2.pdf 2016 [cited 31.10.16]."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1096-9926(200102)63:2<106::AID-TERA1017>3.0.CO;2-R","article-title":"Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child","volume":"63","author":"Brent","year":"2001","journal-title":"Teratology"},{"key":"10.1016\/j.reprotox.2017.04.007_bib0015","unstructured":"Aventis Pharmaceuticals Inc. Arava Tablets (leflunomide). Contraindications and Warnings. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/20905slr007,20905se1-006_arava_lbl.pdf 2003 [cited 31.10.16]."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.reprotox.2007.05.006","article-title":"Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice","volume":"24","author":"Fukushima","year":"2007","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1728-4465.2010.00250.x","article-title":"Unintended pregnancy: worldwide levels, trends, and outcomes","volume":"41","author":"Singh","year":"2010","journal-title":"Stud. Fam. Plann."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0030","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/art.27358","article-title":"Birth outcomes in women who have taken leflunomide during pregnancy","volume":"62","author":"Chambers","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0035","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/art.34419","article-title":"Pregnancy outcome in women exposed to leflunomide before or during pregnancy","volume":"64","author":"Cassina","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0040","first-page":"241","article-title":"The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes","volume":"30","author":"Chakravarty","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0045","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2004.030254","article-title":"Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome","volume":"64","author":"Santis De","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03009742.2011.626442","article-title":"Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers","volume":"41","author":"Viktil","year":"2012","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0055","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2010.140822","article-title":"Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register","volume":"70","author":"Verstappen","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0060","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/rheumatology\/keq132","article-title":"Maternal exposure to leflunomide and methotrexate in a patient with adult-onset Still's disease","volume":"49","author":"Sayarlioglu","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reprotox.2017.04.007_bib0065","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/jp.2008.118","article-title":"A pair of twins born after maternal exposure to leflunomide","volume":"28","author":"Heine","year":"2008","journal-title":"J. Perinatol."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0070","first-page":"281","article-title":"The use of leflunomide in fertile patients with rheumatoid arthritis [engl.Abstract]","volume":"22","author":"Paulus","year":"2006","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0075","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/rheumatology\/kem170","article-title":"Maternal exposure to leflunomide associated with blindness and cerebral palsy","volume":"46","author":"Neville","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reprotox.2017.04.007_bib0080","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.reprotox.2017.04.007_bib0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.reprotox.2008.05.064","article-title":"Using observational cohort data for studying drug effects on pregnancy outcome \u2013 methodological considerations","volume":"26","author":"Schaefer","year":"2008","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0090","unstructured":"World Medical Association WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Subjects. Available from: http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html 2016 [cited 01.11.16]."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0095","unstructured":"EUROCAT. Malformation Coding Guides. Available from: http:\/\/www.eurocat-network.eu\/aboutus\/datacollection\/guidelinesforregistration\/malformationcodingguides 2013 [cited 2016]."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejmg.2016.09.011","article-title":"Human teratogens and genetic phenocopies. Understanding pathogenesis through human genes mutation","volume":"60","author":"Cassina","year":"2017","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1741-4520.2008.00217.x","article-title":"Critical periods for the teratogenicity of immune-suppressant Leflunomide in mice","volume":"49","author":"Fukushima","year":"2009","journal-title":"Congenit. Anom. (Kyoto)"},{"key":"10.1016\/j.reprotox.2017.04.007_bib0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/toxsci\/kfp022","article-title":"Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine","volume":"108","author":"Fukushima","year":"2009","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clim.2011.02.011","article-title":"Immune mechanisms of new therapeutic strategies in MS: teriflunomide","volume":"142","author":"Claussen","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/pds.3744","article-title":"Does the average drug exposure in pregnant women affect pregnancy outcome? A comparison of two approaches to estimate the baseline risks of adverse pregnancy outcome","volume":"24","author":"Wacker","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0125","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.38368","article-title":"Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study","volume":"66","author":"Weber-Schoendorfer","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13052-016-0254-7","article-title":"Incidence of infants born small- and large-for-gestational-age in an Italian cohort over a 20-year period and associated risk factors","volume":"42","author":"Chiavaroli","year":"2016","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.reprotox.2017.04.007_bib0135","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/art.24914","article-title":"Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study","volume":"60","author":"de Man","year":"2009","journal-title":"Arthritis Rheum."}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623817301247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623817301247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:44:43Z","timestamp":1760190283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623817301247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":27,"alternative-id":["S0890623817301247"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2017.04.007","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leflunomide \u2013 A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2017.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}